Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum

Can rewired cells cure some patients' cancer? Do biotech stocks ever go up? And why's it taking so long to get kids vaccinated for Covid-19? Immunologist Katy Rezvani of MD Anderson Cancer Center joins us to explain the massive potential of a new approach to treating wily tumors, one that repurposes human immune cells. We also discuss the latest news in the life sciences, including an interesting hire at Novartis, the pediatric Covid-19 vaccine saga, and another negative milestone for biotech.

Episode metadata supplied by the publisher feed · Published Apr 28, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum

0:00 29:03

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 29 minutes long.

When was this The Readout Loud episode published?

This episode was published on April 28, 2022.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!